Nalmefene Hydrochloride Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution
Available Strengths: 1 mg/mL in 1 mL or 2 mL vials
Reference Brands: Selincro(EU)
Category:
Antipsychotropic Drugs
Nalmefene hydrochloride is an opioid receptor modulator that primarily acts as an antagonist at the μ- and δ-opioid receptors and a partial agonist at the κ-opioid receptor. It is used in emergency settings to reverse opioid overdose, rapidly restoring respiratory function without inducing significant withdrawal symptoms in opioid-dependent individuals.
Nalmefene Hydrochloride Injectable Solution is available in Injectable Solution
and strengths such as 1 mg/mL in 1 mL or 2 mL vials.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nalmefene Hydrochloride Injectable Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nalmefene Hydrochloride Injectable Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nalmefene Hydrochloride Injectable Solution is approved in the USA by the FDA and in the EU under EMA guidelines for the emergency treatment of known or suspected opioid overdose. In the U.S., it is marketed under brand names such as Revex®, while in Europe, it is authorized under strict prescription-only status. Nalmefene’s rapid onset and longer duration of action make it particularly valuable in opioid reversal scenarios, especially in fentanyl-related cases. Manufacturers must comply with cGMP regulations, pharmacovigilance standards, and secure labeling practices. Explore Nalmefene formulations and other opioid antagonists at Pharmatradz.com – your trusted B2B pharma platform.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing